| Compassus-birmingham 2435 1st Avenue South, Irondale, AL, 35210 | |
| (205) 968-9223 |
News Archive
In principle, genetic engineering is simple, but in practice, replacing a faulty gene with a healthy copy is anything but. Using mutated versions of the lamin A gene as an example to demonstrate the versatility of their virus-based approach, researchers at the Salk Institute for Biological Studies successfully edited a diseased gene in patient-specific induced pluripotent stem cells as well as adult stem cells.
IpAuctions, Inc. will auction the worldwide biotherapeutic patents previously owned by Cell Works Inc., a Maryland-based biotech company, and acquired by CellPoint Diagnostics, Inc., based in Mountain View, Calif. These patents primarily consist of organ-targeted drug delivery systems to combat liver disease.
NIBIB researchers have created a nanovaccine that could make a current approach to cancer immunotherapy more effective while also reducing side effects.
A team of Medical University of South Carolina Hollings Cancer Center researchers received a three-year, $1.2 million grant from the U.S. Department of Defens to test a potential therapeutic antibody that could block breast cancer growth with fewer side effects, opening up potential for future drug development.
Research to Prevent Blindness, the leading nonprofit driver of research toward cures and treatments for all blinding disorders, is co-sponsoring a major Institute of Medicine study entitled "Public Health Approaches to Reduce Vision Impairment and Promote Eye Health."
› Verified 4 days ago
| Name | Compassus-birmingham |
|---|---|
| Location | 2435 1st Avenue South, Irondale, Alabama |
| Hospice ID | 011630 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Corporation |
| Profit Type | FOR PROFIT |
| Accreditation Provider | Community Health Accreditation Partner (CHAP) |
| SSA county code | 360 |
News Archive
In principle, genetic engineering is simple, but in practice, replacing a faulty gene with a healthy copy is anything but. Using mutated versions of the lamin A gene as an example to demonstrate the versatility of their virus-based approach, researchers at the Salk Institute for Biological Studies successfully edited a diseased gene in patient-specific induced pluripotent stem cells as well as adult stem cells.
IpAuctions, Inc. will auction the worldwide biotherapeutic patents previously owned by Cell Works Inc., a Maryland-based biotech company, and acquired by CellPoint Diagnostics, Inc., based in Mountain View, Calif. These patents primarily consist of organ-targeted drug delivery systems to combat liver disease.
NIBIB researchers have created a nanovaccine that could make a current approach to cancer immunotherapy more effective while also reducing side effects.
A team of Medical University of South Carolina Hollings Cancer Center researchers received a three-year, $1.2 million grant from the U.S. Department of Defens to test a potential therapeutic antibody that could block breast cancer growth with fewer side effects, opening up potential for future drug development.
Research to Prevent Blindness, the leading nonprofit driver of research toward cures and treatments for all blinding disorders, is co-sponsoring a major Institute of Medicine study entitled "Public Health Approaches to Reduce Vision Impairment and Promote Eye Health."
› Verified 4 days ago
| NPI Number | 1134459084 |
| Organization Name | Hospice Advantage, Llc. |
| Address | 2435 1st Avenue South Irondale, Alabama, 35210 |
| Phone Number | (205)970-3888 |
News Archive
In principle, genetic engineering is simple, but in practice, replacing a faulty gene with a healthy copy is anything but. Using mutated versions of the lamin A gene as an example to demonstrate the versatility of their virus-based approach, researchers at the Salk Institute for Biological Studies successfully edited a diseased gene in patient-specific induced pluripotent stem cells as well as adult stem cells.
IpAuctions, Inc. will auction the worldwide biotherapeutic patents previously owned by Cell Works Inc., a Maryland-based biotech company, and acquired by CellPoint Diagnostics, Inc., based in Mountain View, Calif. These patents primarily consist of organ-targeted drug delivery systems to combat liver disease.
NIBIB researchers have created a nanovaccine that could make a current approach to cancer immunotherapy more effective while also reducing side effects.
A team of Medical University of South Carolina Hollings Cancer Center researchers received a three-year, $1.2 million grant from the U.S. Department of Defens to test a potential therapeutic antibody that could block breast cancer growth with fewer side effects, opening up potential for future drug development.
Research to Prevent Blindness, the leading nonprofit driver of research toward cures and treatments for all blinding disorders, is co-sponsoring a major Institute of Medicine study entitled "Public Health Approaches to Reduce Vision Impairment and Promote Eye Health."
› Verified 4 days ago
| NPI Number | 1588766315 |
| Organization Name | Community Hospices Of America, Inc. |
| Address | 3500 Blue Lake Dr Birmingham, Alabama, 35243 |
| Phone Number | (205)970-3888 |
News Archive
In principle, genetic engineering is simple, but in practice, replacing a faulty gene with a healthy copy is anything but. Using mutated versions of the lamin A gene as an example to demonstrate the versatility of their virus-based approach, researchers at the Salk Institute for Biological Studies successfully edited a diseased gene in patient-specific induced pluripotent stem cells as well as adult stem cells.
IpAuctions, Inc. will auction the worldwide biotherapeutic patents previously owned by Cell Works Inc., a Maryland-based biotech company, and acquired by CellPoint Diagnostics, Inc., based in Mountain View, Calif. These patents primarily consist of organ-targeted drug delivery systems to combat liver disease.
NIBIB researchers have created a nanovaccine that could make a current approach to cancer immunotherapy more effective while also reducing side effects.
A team of Medical University of South Carolina Hollings Cancer Center researchers received a three-year, $1.2 million grant from the U.S. Department of Defens to test a potential therapeutic antibody that could block breast cancer growth with fewer side effects, opening up potential for future drug development.
Research to Prevent Blindness, the leading nonprofit driver of research toward cures and treatments for all blinding disorders, is co-sponsoring a major Institute of Medicine study entitled "Public Health Approaches to Reduce Vision Impairment and Promote Eye Health."
› Verified 4 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 99.2 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 85.2 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 96.9 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 66.7 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 98.4 | 97.3 |
| Patients who got timely treatment for shortness of breath | 95.4 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 81.1 | 93.3 |
News Archive
In principle, genetic engineering is simple, but in practice, replacing a faulty gene with a healthy copy is anything but. Using mutated versions of the lamin A gene as an example to demonstrate the versatility of their virus-based approach, researchers at the Salk Institute for Biological Studies successfully edited a diseased gene in patient-specific induced pluripotent stem cells as well as adult stem cells.
IpAuctions, Inc. will auction the worldwide biotherapeutic patents previously owned by Cell Works Inc., a Maryland-based biotech company, and acquired by CellPoint Diagnostics, Inc., based in Mountain View, Calif. These patents primarily consist of organ-targeted drug delivery systems to combat liver disease.
NIBIB researchers have created a nanovaccine that could make a current approach to cancer immunotherapy more effective while also reducing side effects.
A team of Medical University of South Carolina Hollings Cancer Center researchers received a three-year, $1.2 million grant from the U.S. Department of Defens to test a potential therapeutic antibody that could block breast cancer growth with fewer side effects, opening up potential for future drug development.
Research to Prevent Blindness, the leading nonprofit driver of research toward cures and treatments for all blinding disorders, is co-sponsoring a major Institute of Medicine study entitled "Public Health Approaches to Reduce Vision Impairment and Promote Eye Health."
› Verified 4 days ago
| Home Health Aides | 4 |
| Counselors | 1 |
| Medical Social Workers | 1 |
| Physicians | 2 |
| Registered Nurses | 6 |
| Other Personnel | 4 |
| Total Employees | 18 |
|---|
News Archive
In principle, genetic engineering is simple, but in practice, replacing a faulty gene with a healthy copy is anything but. Using mutated versions of the lamin A gene as an example to demonstrate the versatility of their virus-based approach, researchers at the Salk Institute for Biological Studies successfully edited a diseased gene in patient-specific induced pluripotent stem cells as well as adult stem cells.
IpAuctions, Inc. will auction the worldwide biotherapeutic patents previously owned by Cell Works Inc., a Maryland-based biotech company, and acquired by CellPoint Diagnostics, Inc., based in Mountain View, Calif. These patents primarily consist of organ-targeted drug delivery systems to combat liver disease.
NIBIB researchers have created a nanovaccine that could make a current approach to cancer immunotherapy more effective while also reducing side effects.
A team of Medical University of South Carolina Hollings Cancer Center researchers received a three-year, $1.2 million grant from the U.S. Department of Defens to test a potential therapeutic antibody that could block breast cancer growth with fewer side effects, opening up potential for future drug development.
Research to Prevent Blindness, the leading nonprofit driver of research toward cures and treatments for all blinding disorders, is co-sponsoring a major Institute of Medicine study entitled "Public Health Approaches to Reduce Vision Impairment and Promote Eye Health."
› Verified 4 days ago
| Others | 21 |
| Total Volunteers | 21 |
|---|
News Archive
In principle, genetic engineering is simple, but in practice, replacing a faulty gene with a healthy copy is anything but. Using mutated versions of the lamin A gene as an example to demonstrate the versatility of their virus-based approach, researchers at the Salk Institute for Biological Studies successfully edited a diseased gene in patient-specific induced pluripotent stem cells as well as adult stem cells.
IpAuctions, Inc. will auction the worldwide biotherapeutic patents previously owned by Cell Works Inc., a Maryland-based biotech company, and acquired by CellPoint Diagnostics, Inc., based in Mountain View, Calif. These patents primarily consist of organ-targeted drug delivery systems to combat liver disease.
NIBIB researchers have created a nanovaccine that could make a current approach to cancer immunotherapy more effective while also reducing side effects.
A team of Medical University of South Carolina Hollings Cancer Center researchers received a three-year, $1.2 million grant from the U.S. Department of Defens to test a potential therapeutic antibody that could block breast cancer growth with fewer side effects, opening up potential for future drug development.
Research to Prevent Blindness, the leading nonprofit driver of research toward cures and treatments for all blinding disorders, is co-sponsoring a major Institute of Medicine study entitled "Public Health Approaches to Reduce Vision Impairment and Promote Eye Health."
› Verified 4 days ago
| Compassus-birmingham Location: 2435 1st Avenue South, Irondale, Alabama, 35210 Phone: (205) 968-9223 |